| Oncolytics Ready for Final Clinical Step With Reolysin Bio Tuesday submits: After a 10-year journey, Oncolytics Biotech (TSX:ONC (2.81 ↑0.00%); (NASDAQ:ONCY) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when we started out,” CEO Dr. Brad Thompson said in an exclusive interview with BioTuesday.ca.Complete Story » seekingalpha.com |
Genzyme Ekes Out Profit, Gives Weak View Genzyme posted a $23,000 profit in the second quarter after production problems hit its two biggest-selling drugs. online.wsj.com |
Exelixis, Inc. Q2 2010 Earnings Call Transcript Exelixis, Inc. (EXEL)Q2 2010 Earnings Call TranscriptAugust 5, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Senator Questions McDonald's Health Plans A top Senate Democrat is asking a health insurer that provides plans for McDonald's restaurant workers to disclose details of the plans to the Senate. online.wsj.com |
Clarient, Inc. Shareholder Investigation by Briscoe Law Firm Regarding the Buyout by General Electric Company [Business Wire] - The Briscoe Law Firm, PLLC, founded by a former state prosecutor and enforcement attorney for the United States Securities and Exchange Commission, and the law firm of Powers Taylor, LLP are investigating potential legal claims against the Board of Directors of Clarient, Inc. related to the proposed buy-out of Clarient by General Electric Company. us.rd.yahoo.com |